Efficacy and Safety of Gefitinib in Chinese Lung Cancer Patients
Author Information
Author(s): Wei Zhong, Mengzhao Wang, Li Zhang, Longyun Li, Xiaotong Zhang
Primary Institution: Peking Union Medical College Hospital
Hypothesis
Can gefitinib be an effective treatment for Chinese patients with advanced non-small cell lung cancer and poor performance status?
Conclusion
Gefitinib is well tolerated and beneficial for Chinese patients with poor performance status in advanced non-small cell lung cancer.
Supporting Evidence
- The median overall survival was 10.1 months.
- 40.5% of patients had a partial response to gefitinib.
- Adverse events were mostly mild and reversible.
Takeaway
This study found that a medicine called gefitinib can help some people with a type of lung cancer feel better, even if they are not very strong.
Methodology
42 patients with advanced NSCLC and poor performance status received gefitinib 250 mg/day, and survival rates were analyzed using Kaplan-Meier and Cox regression methods.
Potential Biases
Potential bias due to the non-randomized nature of the study.
Limitations
The study is retrospective and has a small sample size.
Participant Demographics
Chinese patients with advanced non-small cell lung cancer and ECOG performance status of 3-4.
Statistical Information
Confidence Interval
95% CI 3.4–16.8 months
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website